DOCSLIB.ORG

Is 99Mtc-Sestamibi Scintimammography Complementary to Conventional Mammography for Detecting Breast Cancer in Patients with Palpable Masses?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Is 99Mtc-Sestamibi Scintimammography Complementary to Conventional Mammography for Detecting Breast Cancer in Patients with Palpable Masses? Is 99mTc-Sestamibi Scintimammography Complementary to Conventional Mammography for Detecting Breast Cancer in Patients with Palpable Masses? Omar Alonso, Teresa Massardo, Lucı´a B. Delgado, Jorge Horvath, Levent Kabasakal, Augusto Llamas-Olier, Khamza K. Maunda, Rosanna Morales, Ajit K. Padhy, and Uma Ravi Shankar Nuclear Medicine Center, Medical Oncology Department, Medicine Department, and Mammography Unit of Radiology Department, University of Uruguay, Montevideo, Uruguay; Nuclear Medicine Center, University of Chile, Santiago, Chile; Nuclear Medicine Department, Istanbul University, Istanbul, Turkey; Nuclear Medicine Department, National Cancer Institute, Bogota´, Colombia; Department of Nuclear Medicine, Ocean Road Cancer Institute, Dar es Salaam, Tanzania; Nuclear Medicine Department, Peruvian Institute of Nuclear Energy, Lima, Peru; Nuclear Medicine Section, Department of Human Health, International Atomic Energy Agency, Vienna, Austria; and Nuclear Medicine Department, Indraprastha Apollo Hospitals, New Delhi, India Key Words: 99mTc-sestamibi; scintimammography; breast The aim of this trial was to evaluate in developing countries from cancer different regions the diagnostic performance of 99mTc-sestamibi J Nucl Med 2001; 42:1614–1621 scintimammography (SM) in palpable breast lesions and to ver- ify the clinical usefulness of a joint evaluation with mammogra- phy and SM. Methods: From 10 countries, a total of 238 pa- tients with palpable breast masses (n ϭ 245) were included in this prospective multicenter trial. Prone SM was performed 10 Breast cancer is by far the most common malignancy min and 60–90 min (157 patients) after injection using an isotime among women worldwide, and 41% of all new cases are acquisition of 10 min. Mammography was assessed by the diagnosed in developing countries (1). In these countries, same dedicated imaging radiologist according to breast imag- 323,000 cases were detected in 1990, leading to 140,000 ing reporting and data system (BI-RADS) categories for malig- deaths (1,2). Furthermore, as the population increases and nancy and breast density. Masked SM findings and mammog- ages, the number of new cases in these countries is expected raphy findings were checked for a correlation with to increase dramatically (3). histopathology findings for excisional biopsy samples. Diagnos- tic values for breast cancer detection were calculated per le- Mammography represents the only validated imaging sion. Results: Histopathology revealed 189 cancerous lesions technique for breast cancer screening. Several randomized and 56 benign lesions. The sensitivity and specificity of SM were controlled trials have reported about a 30% mortality reduc- 0.83 and 0.77, respectively. SM diagnostic values did not de- tion in women older than 50 y using this procedure (4). pend on the incidence of breast cancer in the country of origin However, the technique is less reliable for detecting lesions or on the timing of imaging (early vs. delayed scans). On mam- in women younger than 50 y, in whom dense, glandular mography, the technique yielded a sensitivity and specificity of breasts are a common radiographic finding, yielding a false- 0.85 and 0.66, with 27 mammograms classified as BI-RADS category 1, 33 as category 2, 5 as category 3, 56 as category 4, negative rate of 25%–45% (5). Therefore, frequent delays and 124 as category 5. Thirty-seven lesions were considered to in the diagnosis of breast cancer are seen in this group and show increased radiologic density. No significant difference was are associated with significantly shorter survival (6). Fur- found in SM diagnostic values among different BI-RADS cate- thermore, the positive predictive value of mammography is gories or between the groups with low and high breast density. reported to be Ͻ40% (7), resulting in many unnecessary A sensitivity of 96% was calculated when SM and mammogra- biopsies. phy results were combined, with 75% of all false-negative mam- Since the publication of the encouraging results of mography findings classified as true-positive results by SM. 99m Conclusion: SM complements mammography in patients with Khalkhali et al. (8) for Tc-sestamibi scintimammography palpable masses and negative mammography findings. (SM), several investigators have reported on the clinical value of the technique and its possible complementary role to mammography for the evaluation of primary breast can- Received Feb. 22, 2001; revision accepted Jul. 13, 2001. cer (9–12). One of the proposed clinical indications for SM For correspondence or reprints contact: Omar Alonso, MD, Centro de Medicina Nuclear, Hospital de Clı´nicas,Avenida Italia s/n, Montevideo 11600, was palpable masses not clearly seen or classified as inde- Uruguay. terminate or benign on mammography (10,11). Therefore, a 1614 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 42 • No. 11 • November 2001 multicenter trial sponsored by the International Atomic En- SM ergy Agency was set up to evaluate—in developing coun- Labeling and quality control of 99mTc-sestamibi were performed tries from different geographic regions—the diagnostic val- according to the manufacturer’s instructions (DuPont Pharmaceu- ues of SM in palpable breast lesions and the clinical ticals Co., Billerica, MA). The radiochemical purity of the radio- usefulness of an imaging protocol based on the joint appli- pharmaceutical was always Ն90%. 99mTc-sestamibi was injected through an indwelling catheter cation of mammography and SM. into the arm contralateral to the palpable breast lesion, and the catheter was then flushed with 10 mL saline. In patients with MATERIALS AND METHODS bilateral lesions, the injection was into a dorsal vein of the foot. The dose ranged from 740 to 1,110 MBq (20–30 mCi). Trial Design and Patients Planar scanning was started 10 min after injection of the tracer, The study was organized as a prospective open-label multi- beginning with the affected breast. Lateral views were acquired center trial. To be included, a patient had to be a nonpregnant with the patient lying prone, using a commercially available pad woman who had given informed consent and who had a palpable set (Pinestar Technology, Greenville, PA) designed to support the breast lesion as determined by an experienced surgeon, mammo- patient’s head, shoulders, and arms, allowing the imaged breast to grams obtained within 4 wk of SM, and a histopathologic report on depend while compressing the opposite breast. An anterior tho- an excisional biopsy specimen. Exclusion criteria included previ- racic view including both axillae was also obtained while the ous surgery for a palpable breast lesion, fine-needle biopsy within patient was supine with her arms raised behind her head. Delayed 1 wk before SM or core biopsy during the preceding 4 wk, prior imaging, 60–90 min after injection, was performed on 157 patients chemo- or radiotherapy, and lack of a histopathologic report. We (160 lesions). Images were acquired on a 256 ϫ 256 matrix, using received data for 346 patients from 10 countries in Africa, Asia, a 10% window centered on an energy peak of 140 keV. We used Europe, Latin America, and the Middle East: Chile (n ϭ 44), an isotime acquisition of 10 min for each view. A low-energy China (n ϭ 36), Colombia (n ϭ 39), Cuba (n ϭ 16), Greece (n ϭ high-resolution collimated gamma camera was used, with appro- 42), India (n ϭ 23), Peru (n ϭ 44), Tanzania (n ϭ 13), Turkey priate zooming for lateral views to include axillae, breast, and (n ϭ 52), and Uruguay (n ϭ 37). The age-standardized annual chest wall. The distance between the breast and the detector was incidence rates of breast cancer, as estimated in 1990 (1), in minimized. participating countries is summarized in Table 1 and ranges from 11.77 (China) to 87.59 (Uruguay), with a median of 29.19. Mammography The efficacy population of the trial consisted of 238 patients For all patients, mammography was performed using craniocau- (245 lesions, 7 patients with bilateral tumors), after 108 patients dal and mediolateral oblique views. Mammograms were sent to a were excluded because of inappropriate scintigraphy technique core-center dedicated breast-imaging radiologist, who evaluated (n ϭ 14), lack of mammograms (n ϭ 49), incomplete mammo- them according to the breast imaging reporting and data system grams with a recommendation for additional imaging (n ϭ 8), lack (BI-RADS) developed by the American College of Radiology of tissue diagnosis (n ϭ 20), or nonpalpable lesions (n ϭ 17). (Reston, VA) (13). The radiologist was unaware of histopathology The median age of the patients was 50 y (range, 19–84 y). In and SM findings, but physical examination data were available to 12% of patients, a family history of breast cancer was documented. him. Mammograms were considered positive for malignancy if the Oral contraceptives and hormone replacement therapy had been BI-RADS score was Ն4. When additional imaging was recom- used in 16% and 8% of patients, respectively. Prior surgery for mended, patients were scored as BI-RADS category 0 and ex- cancer of the contralateral breast had been performed on 4% of cluded from the efficacy population (n ϭ 8). Breast density was patients. Pre-, peri-, and postmenopausal status was present in also scored according to the BI-RADS system, with 1 ϭ entirely 41%, 7%, and 52% of patients, respectively. fatty, 2 ϭ fatty with scattered fibroglandular tissue, 3 ϭ hetero- geneously dense, and 4 ϭ extremely dense (13). Increased radio- logic density was documented for patients with scores of 3 or 4. TABLE 1 Masked Interpretation of SM Age-Standardized Annual Incidence Rates of Breast The SM films were read by 2 independent, experienced nuclear Cancer in Participating Countries medicine physicians who were unaware of the clinical status of the patient, physical examination findings, mammography findings, Country Incidence and histopathologic results. Initial and delayed images were scored China 11.77 separately by the readers, who did not know whether the images Tanzania 13.61 were from the same patient.
Load more

Recommended publications
  • BREAST IMAGING for SCREENING and DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017
    Oxford UnitedHealthcare® Oxford Clinical Policy BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Omnibus Codes CONDITIONS OF COVERAGE ...................................... 1 Preventive Care Services BENEFIT CONSIDERATIONS ...................................... 2 Radiology Procedures Requiring Precertification for COVERAGE RATIONALE ............................................. 3 eviCore Healthcare Arrangement APPLICABLE CODES ................................................. 5 DESCRIPTION OF SERVICES ...................................... 6 CLINICAL EVIDENCE ................................................. 7 U.S. FOOD AND DRUG ADMINISTRATION ................... 16 REFERENCES .......................................................... 18 POLICY HISTORY/REVISION INFORMATION ................ 22 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms
    [Show full text]
  • Breast Scintimammography
    CLINICAL MEDICAL POLICY Policy Name: Breast Scintimammography Policy Number: MP-105-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 11/23/2020 Issue Date: 11/23/2020 Effective Date: 12/21/2020 Next Annual Review: 10/2021 Revision Date: 09/16/2020 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 5 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ does not provide coverage in the Company’s Medicaid products for breast scintimammography. The service is considered experimental and investigational in all applications, including but not limited to use as an adjunct to mammography or in staging the axillary lymph nodes. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-105-MD-PA Page 1 of 5 DEFINITIONS Prior Authorization Review Panel – A panel of representatives from within the Pennsylvania Department of Human Services who have been assigned organizational responsibility for the review, approval and denial of all PH-MCO Prior Authorization policies and procedures. Scintimammography A noninvasive supplemental diagnostic testing technology that requires the use of radiopharmaceuticals in order to detect tissues within the breast that accumulate higher levels of radioactive tracer that emit gamma radiation.
    [Show full text]
  • Procedure Guideline for Breast Scintigraphy
    Procedure Guideline for Breast Scintigraphy Iraj Khalkhali, Linda E. Diggles, Raymond Taillefer, Penny R. Vandestreek, Patrick J. Peller and Hani H. Abdel-Nabi Harbor-UCLA Medical Center, Terranee; Nuclear Imaging Consultants, Roseville, California; Hospital Hôtel-Dieu de Montreal, Montreal, Quebec, Canada; Lutheran General Hospital, Park Ridge, Illinois; and University of Buffalo, Buffalo, New York Key Words: breast scintigraphy;procedureguideline should be available, as well as sonograms, if J NucíMed 1999; 40:1233-1235 obtained. 2. A breast physical examination must be performed by either the nuclear medicine physician or the PART I: PURPOSE referring physician. 3. The time of last menses and pregnancy and lactat- The purpose of this guideline is to assist nuclear medicine ing status of the patient should be determined. practitioners in recommending, performing, interpreting and reporting the results of 99mTc-sestamibi breast scintigraphy 4. Breast scintigraphy should be delayed at least 2 wk after cyst or fine-needle aspiration, and 4—6wk (mammoscintigraphy, scintimammography). after core or excisional biopsy. 5. The nuclear medicine physician should be aware of PART II: BACKGROUND INFORMATION AND DEFINITIONS physical signs and symptoms and prior surgical procedures or therapy. Breast scintigraphy is performed after intravenous admin istration of "mTc-sestamibi and includes planar and/or C. Precautions None SPECT. D. Radiopharmaceutical 1. Intravenous injection of 740-1110 MBq (20-30 PART III: COMMON INDICATIONS AND APPLICATIONS mCi) 99mTc-sestamibi should be administered in an A. Evaluate breast cancer in patients in whom mammog- arm vein contralateral to the breast with the sus raphy is not diagnostic or is difficult to interpret (e.g., pected abnormality.
    [Show full text]
  • A Molecular Approach to Breast Imaging
    Journal of Nuclear Medicine, published on January 16, 2014 as doi:10.2967/jnumed.113.126102 FOCUS ON MOLECULAR IMAGING A Molecular Approach to Breast Imaging Amy M. Fowler Department of Radiology, University of Wisconsin–Madison, Madison, Wisconsin malignant cells. A recent meta-analysis of the accuracy of 99mTc-sestamibi scintimammography as an adjunct to di- Molecular imaging is a multimodality discipline for noninvasively agnostic mammography for detection of breast cancer dem- visualizing biologic processes at the subcellular level. Clinical applications of radionuclide-based molecular imaging for breast onstrated a sensitivity of 83% and specificity of 85% (2). cancer continue to evolve. Whole-body imaging, with scinti- However, sensitivity was less for nonpalpable (59%) versus mammography and PET, and newer dedicated breast imaging palpable lesions (87%) despite comparable specificity, with systems are reviewed. The potential clinical indications and the no significant difference between planar and SPECT meth- challenges of implementing these emerging technologies are ods. Decreased sensitivity for nonpalpable, presumably presented. smaller, lesions is in part due to the limited spatial resolu- Key Words: molecular imaging; oncology; breast; PET; PET/ tion of conventional g cameras. CT; radiopharmaceuticals; breast cancer; breast-specific g im- In addition to 99mTc-sestamibi, the positron-emitting ra- aging; positron-emission mammography; positron-emission to- diopharmaceutical 18F-FDG accumulates in many types of mography cancer including breast. Meta-analyses of the accuracy of J Nucl Med 2014; 55:1–4 whole-body 18F-FDG PET used after standard diagnostic DOI: 10.2967/jnumed.113.126102 workup for patients with suspected breast lesions demon- strated sensitivities of 83%–89% and specificities of 74%– 80% (3,4).
    [Show full text]
  • Evaluation of Nipple Discharge
    New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55].
    [Show full text]
  • Evaluation of the Quantitative Accuracy of a Commercially-Available Positron Emission Mammography Scanner
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2010 EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER Adam Springer Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Diagnosis Commons, Equipment and Supplies Commons, and the Other Medical Sciences Commons Recommended Citation Springer, Adam, "EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER" (2010). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 64. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/64 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY- AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER
    [Show full text]
  • General User Charges in AIIMS Raipur
    General User Charges in AIIMS Raipur S No. Name of General Charges Paying Ward General Remark Ward/OPD 1 Registration Charges 200 25 2 Bed Charges Per Day (Sami 2000 35 Patients being adm Deluxe) itted in 3 Bed Charges Per Day (Deluxe) 3000 35 Paying/General 4 Diet Charges Per Day 200 Optional Nil ward will pay an advance for 10 days charges at the time of admission. 5 ICU/NICU/PICU/CCU Charges 1000 (Above & 300 Per Day Over to Bed Charge 6 Minor Operation in OT/MOT 250 100 not mentioned in list, under L A 7 Minor Operation in OT/MOT 1000 300 not mentioned in list, under G A 8 Major Operation in OT, Not 2000 1000 mentioned in list under G A 9 Medical Certificate (Sickness) 10 10 10 Medical Certificate (Fitness) 10 10 11 Tubectomy / Laparoscopic 25 20 Sterilization 12 Death file charges 25 25 13 Medico Legal Injury Report 50 50 (MLR) 14 Birth / Death Certificate 1st 0 0 Copy 15 Birth / Death Certificate 5 5 Subsequent Copy 16 Additional correction in Birth 10 10 / Death / certificate 17 Completion of LIC / Insurance 50 50 claim file 18 Subsequent Pass if on special 50 50 condition 19 Supply of blood (One Unit) 250 75 1 20 Medical Board Certificate 500 500 On Special Case User Charges for Investigations in AIIMS Raipur S No. Name of Investigations Paying General Remark Ward Ward/OPD Anaesthsia 1 ABG 75 50 2 ABG ALONGWITH 150 100 ELECTROLYTES(NA+,K+)(Na,K) 3 ONLY ELECTROLYTES(Na+,K+,Cl,Ca+) 75 50 4 ONLY CALCIUM 50 25 5 GLUCOSE 25 20 6 LACTATE 25 20 7 UREA.
    [Show full text]
  • Scintimammography and Gamma Imaging of the Breast and Axilla
    MEDICAL POLICY POLICY TITLE SCINTIMAMMOGRAPHY AND GAMMA IMAGING OF THE BREAST AND AXILLA POLICY NUMBER MP-5.021 Original Issue Date (Created): 8/9/2002 Most Recent Review Date (Revised): 8/18/2020 Effective Date: 11/1/2020 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY I. POLICY Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) are considered investigational in all applications, including but not limited to its use as an adjunct to mammography or in staging the axillary lymph nodes. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with these procedures. Use of gamma detection following radiopharmaceutical administration for localization of sentinel lymph nodes in patients with breast cancer may be considered medically necessary. Policy Guidelines The most commonly-used radiopharmaceutical in breast-specific gamma imaging or molecular breast imaging is technetium 99m (Tc-99m) sestamibi. The most commonly used radiopharmaceuticals for sentinel lymph node detection using either lymphoscintigraphy or hand-held gamma detection include Tc 99mlabeled colloids (eg, sulfur colloid). Cross-references: MP-5.022 Radioimmunoscintigraphy Imaging Monoclonal Antibody Imaging with Indium- 111 Capromab Pendetide for Prostate Cancer II. PRODUCT VARIATIONS Top This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below. Page 1 MEDICAL POLICY POLICY TITLE SCINTIMAMMOGRAPHY AND GAMMA IMAGING OF THE BREAST AND AXILLA POLICY NUMBER MP-5.021 III. DESCRIPTION/BACKGROUND Top Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) use radiotracers with nuclear medicine imaging as a diagnostic tool for abnormalities of the breast.
    [Show full text]
  • Scintimammography with a Hybrid SPECT/CT Imaging System
    ANTICANCER RESEARCH 27: 557-562 (2007) Scintimammography with a Hybrid SPECT/CT Imaging System ORAZIO SCHILLACI, ROBERTA DANIELI, LUCA FILIPPI, PASQUALE ROMANO, ELSA COSSU, CARLO MANNI and GIOVANNI SIMONETTI Department of Biopathology and Diagnostic Imaging, University "Tor Vergata", Rome, Italy Abstract. Background: Planar scintimammography is useful carcinomas are evident on mammograms, especially in dense for characterizing breast lesions >10 mm. Our aim was to or dysplastic breasts (3); moreover, its specificity and positive evaluate Tc-99m sestamibi scintimammography with a hybrid predictive value are low because it cannot always (SPECT/CT) device for functional anatomical mapping (FAM). differentiate benign lesions from malignant ones (4). The Patients and Methods: Three planar images and a chest drawbacks of mammography have led to the development of SPECT/CT were performed with a hybrid device in 53 patients complementary modalities for breast cancer imaging, with mammographically suspicious lesions. The final including scintimammography, a nuclear medicine technique histopathological diagnosis was obtained after surgery. Results: that uses radiopharmaceuticals to detect malignant breast The planar images were positive in 27 out of 37 carcinomas tumours (5, 6). Scintimammography is conventionally (sensitivity 73%) and the SPECT/CT in 33 (sensitivity 89.2%). performed with planar acquisitions, which have a low The sensitivity of planar imaging and SPECT/CT was 42.9% sensitivity for lesions ≤10 mm (5). Recently, a new imaging and 71.4% in cancers ≤10 mm, and 91.3%, and 100% in device combining a dual-head, variable angle gamma camera cancers >10 mm, respectively. The specificity was 93.8% for with a low-dose X-ray tube has been introduced (7): this both planar and SPECT/CT imaging; accuracy was 79.2% for hybrid gamma camera/CT scanner provides cross-sectional planar scans and 90.6% for SPECT/CT.
    [Show full text]
  • SNMMI Nuclear Medicine Technology Competency Based Curriculum
    Nuclear Medicine Technology Competency- Based Curriculum Guide 5th Edition Introduction Competency-based education in nuclear medicine technology focuses on those elements necessary to become an entry-level nuclear medicine technologist. Emphasizing competencies communicates entry-level knowledge, skills, attitudes, and behaviors that the nuclear medicine technology curriculum must address and that employers can expect of graduates. Competency- based education allows more flexibility in pedagogical approaches to achieve these essential competencies. The competencies are divided into eight sections: 1. Radiation Safety 2. Instrumentation, Quality Control and Quality Assurance 3. Radiopharmacy and Pharmacology 4. Diagnostic and Therapeutic Procedures 5. Patient Care 6. Professionalism and Interpersonal Communication Skills 7. Organization Systems-Based Practice 8. Research Methodology Each section lists the competencies that must be achieved by the entry level nuclear medicine technologist. The rigor of the nuclear medicine technologist entry-level competencies is such that a significant body of knowledge, skills, and experience is necessary to achieve them. This level of rigor is consistent with the Society of Nuclear Medicine and Molecular Imaging—Technologist Section’s (SNMMI-TS) recommendation that the entry-level degree for a nuclear medicine technologist should be at the baccalaureate level. The content listed under the competencies is intended to be used as a guide for what may be included in a program’s curriculum to achieve minimal competency in each area. The specific content listed should be used at the program’s discretion to meet individual curricular and accreditation needs. The content in its entirety is not considered mandatory, and other pedagogies may equally meet each program’s needs.
    [Show full text]
  • Infrequently Performed Studies in Nuclear Medicine: Part 1
    Infrequently Performed Studies in Nuclear Medicine: Part 1 Anita MacDonald and Steven Burrell Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada clinical and technical aspects of each study are discussed, Nuclear medicine is a diverse field with a large number of differ- along with a brief comparison of alternative assessment ent studies spanning virtually all organ systems and medical spe- modalities. Included in Part 1 of this article are dacroscin- cialties. Many nuclear medicine procedures are performed tigraphy, LeVeen shunts, scintimammography, right-to-left routinely; others may be performed only rarely, sometimes less (R-L) shunts, left-to-right (L-R) shunts, and heat-damaged than once per year. The infrequent nature of many studies makes it challenging to retain relevant knowledge and skills. This 2-part red blood cell (RBC) studies. Part 2 will cover cerebral article provides a review of several infrequently performed stud- spinal fluid shunt, brain death, testicular scan, quantitative ies. The topics discussed in Part 1 include dacroscintigraphy, lung perfusion scan, lymphoscintigraphy, and salivary gland LeVeen shunts, scintimammography, right-to-left shunts, left- scintigraphy studies. to-right shunts, and heat-damaged red blood cells. After reading this article, the reader should be able to list and describe the in- DACROSCINTIGRAPHY (LACRIMAL GLAND STUDY) dications for each study, list the doses and describe their proper method of administration, and describe problems that may arise The lacrimal glands are located in the lateral superior during the imaging procedure and how they should be handled. portion of each orbit.
    [Show full text]
  • Society of Nuclear Medicine Procedure Guideline for Breast Scintigraphy Version 2.0, Approved June 2, 2004
    Society of Nuclear Medicine Procedure Guideline for Breast Scintigraphy Version 2.0, approved June 2, 2004 Authors: Iraj Khalkhali, MD (Harbor-UCLA Medical Center, Torrance, CA); Gina Caravaglia, MD (Harbor-UCLA Medical Center, Torrance, CA); Hani H. Abdel-Nabi, MD, PhD (University of Buffalo, Buffalo, NY); Patrick J. Peller, MD (Woodburn Nuclear Medicine, Annandale, VA); Raymond Taillefer, MD (Hospital Hotel-Dieu de Montreal, Montreal, Quebec, Canada); Penny R. Vande Streek, DO (Sutter Roseville Medical Center, Roseville, CA); and Christophe Van de Wiele, MD (Universitair Ziekenhuis, Ghent, Belgium). I. Purpose carcinomas in patients with tissue diagnosis of breast cancer. The purpose of this guideline is to assist nuclear C. May be useful in the evaluation of the effective- medicine practitioners in recommending, performing, 99m ness of neoadjuvant chemotherapy for breast car- interpreting, and reporting the results of Tc- cinoma. sestamibi breast scintigraphy (mammoscintigraphy, scintimammography). IV. Procedure II. Background Information and Definitions A. Patient Preparation 1. No special preparation for the test is needed; Breast scintigraphy is performed after intravenous 99m however, a thorough explanation of the test administration of Tc-sestamibi and includes planar should be provided by the technologist or and/or single-photon emission computed tomography physician. Before radiopharmaceutical injec- (SPECT). tion, the technologist may have the patient at- tempt the prone position with arms extended, III. Examples of Clinical or Research to assess the feasibility of the study. Applications 2. The patient should remove all clothing and jewelry above the waist and should wear a A. Evaluate breast cancer in patients in whom hospital gown open in front.
    [Show full text]